How does BG-12 work? According to MedicalNewsToday (MNT) [4], "…BG-12 is the first compound that has been shown to activate a transcription pathway, which previous studies have shown defends against oxidative-stress induced neuronal death, protects the blood-brain barrier, and supports maintenance of myelin integrity in the central nervous system.."
_In other words BG-12 compound enhances the body's normal cellular protection pathways._
74% is an enormous majority. Granted, this is just a survey by Decision Resources. But, according to MarketWatch, a DowJones company, Decision Resources carries some weight.
What would happen then to the other new MS medications?
* Sanofi's Aubagio,
* Teva/Active Biotech's oral laquinimod,
* Genzyme/Sanofi/Bayer HealthCare's intravenous anti-CD52 monoclonal antibody Lemtrada.
According to MarketWatch, the news about Gilenya is not that good: "….about one-third of Gilenya prescribers and one-quarter of payers believe Gilenya's annual cost is commensurate with its clinical value…"
_U.S. Physician & Payer Forum report shows U.S. neurologists prescribing those drugs substantially less frequently than BG-12_
Interestingly, Ocrelizumab, which is also a promising drug [3], is not mentioned in the MarketWatch article.
So, the race for the second generation MS drugs is not over until the prescriptions are actually filled
_This competition is actually very good news for the new MS patient._
_**Talk to your Doctor**_
_**Sources:**_
[1][ Marketwatch][1] ; "Seventy-Four Percent of Surveyed U.S. Neurologists Indicate They Will Prescribe Biogen Idec's BG-12 for the Treatment of Relapsing-Remitting Multiple Sclerosis"; Nov. 28, 2011
[2][ Decision Resources ][2]; "Multiple Sclerosis (Event Driven)
[3][ MediNewsDigest][3] ; "…New Drug Classes For Multiple Sclerosis Are Coming: Just In or Clinical Trials.." ; November 3, 2011
[4][ MedicalNewsToday][4] ; "BG-12, Biogen Idec's Novel Oral Compound Shown To Significantly Reduced Brain Lesions In Patients With Multiple Sclerosis"; 26 Oct 2008
[5] [Answers.com][5]
Technorati Tags: [BG-12][6], [Gilenya][7], [Lemtrada][8], [multiple sclerosis][9], [New MS Drugs][10], [Sanofi's Aubagio][11], [Teva/Active Biotech's oral laquinimod][12]
[![Email][13]][14][![Share][15]][16]
[1]: http://www.marketwatch.com/story/seventy-four-percent-of-surveyed-us-neurologists-indicate-they-will-prescribe-biogen-idecs-bg-12-for-the-treatment-of-relapsing-remitting-multiple-sclerosis-2011-11-28?reflink=MW_news_stmp
[2]: http://decisionresources.com/Products-and-Services/Report?r=pcorcg0511
[3]: http://www.medinewsdigest.com/?p=3107
[4]: http://www.medicalnewstoday.com/releases/126804.php
[5]: http://www.answers.com/topic/transcription-factor
[6]: http://technorati.com/tag/BG-12
[7]: http://technorati.com/tag/Gilenya
[8]: http://technorati.com/tag/Lemtrada
[9]: http://technorati.com/tag/multiple+sclerosis
[10]: http://technorati.com/tag/New+MS+Drugs
[11]: http://technorati.com/tag/Sanofi%27s+Aubagio
[12]: http://technorati.com/tag/Teva%2FActive+Biotech%27s+oral+laquinimod
[13]: http://www.medinewsdigest.com/wp-content/plugins/add-to-any/icons/email.png
[14]: http://www.addtoany.com/add_to/email?linkurl=http%3A%2F%2Fwww.medinewsdigest.com%2F%3Fp%3D3228&linkname=Survey%20Shows%20Vast%20Majority%20of%20Neurologists%20Expect%20%20To%20Prescribe%20Emerging%20Drug%20BG-12%20Against%20Relapsing%20Remitting%20%20Multiple%20Sclerosis (Email)
[15]: http://www.medinewsdigest.com/wp-content/plugins/add-to-any/share_save_256_24.png
[16]: http://www.addtoany.com/share_save#url=http%3A%2F%2Fwww.medinewsdigest.com%2F%3Fp%3D3228&title=Survey%20Shows%20Vast%20Majority%20of%20Neurologists%20Expect%20%20To%20Prescribe%20Emerging%20Drug%20BG-12%20Against%20Relapsing%20Remitting%20%20Multiple%20Sclerosis
No comments:
Post a Comment